Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer
- PMID: 19399748
- DOI: 10.1002/cncr.24283
Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer
Abstract
Androgen-deprivation therapy (ADT) is a common treatment for men with prostate cancer. Although ADT is effective at suppressing prostate-specific antigen (PSA), stabilizing disease, alleviating symptoms in advanced disease, and potentially prolonging survival, it is not without serious side effects. However, to the authors' knowledge, there is lack of a systematic review of its major adverse effects to date. The authors of this report systematically reviewed and quantitatively assessed the literature on skeletal and cardiac side effects associated with ADT in men with prostate cancer. The PubMed database was searched for relevant published articles from 1966 to May 2008, and 683 articles were reviewed systematically from an original 20 different Medical Subject Heading search combinations. The focus of the review was on bone-related and cardiovascular-related outcomes. When appropriate, results were pooled from articles on specific adverse outcomes, summary risk estimates were calculated, and tests of heterogeneity were performed. Fourteen articles were identified that met inclusion criteria from the original 683 studies. Men who underwent ADT for prostate cancer had a significantly increased risk of overall fracture of 23% (summary relative risk, 1.23; 95% confidence interval [95% CI], 1.10-1.38) compared with men who had prostate cancer but who did not undergo ADT. Furthermore, men who underwent ADT had a 17% increase in cardiovascular-related mortality compared with men who did not undergo with ADT (summary hazards ratio, 1.17; 95% CI, 1.07-1.29). Significant elevations in the risk of diabetes also were observed from 2 large studies. ADT was associated with an increased risk of skeletal fracture, incident diabetes, and cardiovascular-related mortality, although the absolute risk of these events was low. Preventive measures against these adverse effects and careful assessment of patient's baseline health status should be considered.
(c) 2009 American Cancer Society.
Similar articles
-
Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?Clin Endocrinol (Oxf). 2011 Mar;74(3):289-93. doi: 10.1111/j.1365-2265.2010.03939.x. Clin Endocrinol (Oxf). 2011. PMID: 21092052
-
Androgen deprivation therapy: evidence-based management of side effects.BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23351025 Review.
-
Androgen deprivation in veterans with prostate cancer: implications for skeletal health.Ann Pharmacother. 2006 Dec;40(12):2107-14. doi: 10.1345/aph.1H209. Epub 2006 Nov 28. Ann Pharmacother. 2006. PMID: 17132807
-
Fracture risk in patients with prostate cancer on androgen deprivation therapy.Osteoporos Int. 2005 Jun;16(6):707-11. doi: 10.1007/s00198-004-1799-7. Epub 2005 Feb 16. Osteoporos Int. 2005. PMID: 15714259
-
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. doi: 10.1210/jc.2007-2595. Epub 2008 Mar 18. J Clin Endocrinol Metab. 2008. PMID: 18349064 Review.
Cited by
-
Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.Eur Urol. 2017 Mar;71(3):340-348. doi: 10.1016/j.eururo.2016.08.055. Epub 2016 Sep 3. Eur Urol. 2017. PMID: 27597240 Free PMC article.
-
Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.Nat Rev Urol. 2017 Jan;14(1):15-25. doi: 10.1038/nrurol.2016.175. Epub 2016 Oct 11. Nat Rev Urol. 2017. PMID: 27725639 Free PMC article. Review.
-
Attention to the principles of exercise training in exercise studies on prostate cancer survivors: a systematic review.BMC Cancer. 2019 Apr 5;19(1):321. doi: 10.1186/s12885-019-5520-9. BMC Cancer. 2019. PMID: 30953460 Free PMC article.
-
Histopathological concordance between prostate biopsies and radical prostatectomy specimens-implications of transrectal and transperineal biopsy approaches.Prostate Cancer Prostatic Dis. 2024 Jun;27(2):312-317. doi: 10.1038/s41391-023-00714-x. Epub 2023 Sep 2. Prostate Cancer Prostatic Dis. 2024. PMID: 37660218
-
Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study.Medicine (Baltimore). 2016 Feb;95(6):e2789. doi: 10.1097/MD.0000000000002789. Medicine (Baltimore). 2016. PMID: 26871838 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous